Bai et al. found an OR of 0.63 (95% CI 0.20–1.98) for pericardial effusion when comparing anti-PD-L1 combined versus bevacizumab with anti-PD-L1 monotherapy [14]. The gene discussed is CD274; the disease is pericardial effusion.